A nationwide evaluation of deceased donor kidney transplantation indicates detrimental consequences of early graft loss
Kok, M.J. de; Schaapherder, A.F.; Mensink, J.W.; Vries, A.P. de; Reinders, M.E.; Konijn, C.; ...; Lindeman, J.H.

Citation

Version: Publisher's Version
License: Creative Commons CC BY 4.0 license
Downloaded from: https://hdl.handle.net/1887/3185012

Note: To cite this publication please use the final published version (if applicable).
Early graft loss (EGL) is a feared outcome of kidney transplantation. Consequently, kidneys with an anticipated risk of EGL are declined for transplantation. In the most favorable scenario, with optimal use of available donor kidneys, the donor pool size is balanced by the risk of EGL, with a tradeoff dictated by the consequences of EGL. To gauge the consequence of EGL we systematically evaluated its impact in an observational study that included all 10,307 deceased-donor kidney transplantsations performed in the Netherlands between 1990 and 2018. Incidence of EGL, defined as graft loss within 90 days, in primary transplantation was 8.2% (699/8,511). The main causes were graft rejection (30%), primary nonfunction (25%), and thrombosis or infarction (20%). EGL profoundly impacted short- and long-term patient survival (adjusted hazard ratio; 95% confidence interval: 8.2; 5.1-13.2 and 1.7; 1.3-2.1, respectively). Of the EGL recipients who survived 90 days after transplantation (617/699) only 440 of the 617 were relisted for re-transplantation. Of those relisted, only 298 were ultimately re-transplanted leading to an actual re-transplantation rate of 43%. Noticeably, re-transplantation was associated with a doubled incidence of EGL, but similar long-term graft survival (adjusted hazard ratio 1.1; 0.6-1.8). Thus, EGL after kidney transplantation is a medical catastrophe with high mortality rates, low relisting rates, and increased risk of recurrent EGL following re-transplantation. This implies that detrimental outcomes also involve convergence of risk factors in recipients with EGL. The 8.2% incidence of EGL minimally impacted population mortality, indicating this incidence is acceptable.

**KEYWORDS:** deceased-donor kidney transplantation; early graft loss; graft survival; patient survival; primary nonfunction; re-transplantation

EGL is also considered a catastrophic outcome of kidney transplantation. As a consequence, when donor kidneys are expected to have an increased risk of EGL, they are declined for transplantation. Although a permissive policy toward anticipated high-risk organs will result in an unacceptable high incidence of EGL, a more reticent attitude will compromise the donor use and, as such, contribute to increasing organ shortages and longer waiting-list times. Consequently, in a scenario with optimal use of available donor kidneys, the size of the donor pool is balanced by the risk of EGL, with the trade-off dictated by the impact of EGL.

To date, only 2 single-center studies have evaluated the consequences of EGL after kidney transplantation.\(^1,2\) The authors concluded that EGL had a detrimental impact on short- and long-term patient survival. However, the low number of EGL cases did not allow an in-depth evaluation.\(^1,2\)

Given the persistent donor organ shortage and the need to expand the donor pool without compromising outcomes, we considered a systematic, adequately powered evaluation of the
Table 1 | Descriptive characteristics of recipients with and without early graft loss after a first transplant procedure

<table>
<thead>
<tr>
<th>EGL</th>
<th>Non-EGL</th>
</tr>
</thead>
<tbody>
<tr>
<td>n 699 (8.2%)</td>
<td>n 7812 (91.8%)</td>
</tr>
</tbody>
</table>

**Donor**
- Donor type (% DCD): 222 (31.8) vs. 2394 (30.6) 0.541
- Age (yr): 49.8 ± 15.6 vs. 46.7 ± 16.3 <0.001
- Sex (% male): 381 (54.5) vs. 4228 (54.1) 0.845
- Height (cm): 173.0 vs. 175.0 0.007
- Weight (kg): 76.1 ± 17.6 vs. 75.5 ± 15.9 0.372
- BMI (kg/m²): 25.6 ± 5.0 vs. 24.8 ± 4.2 0.001
- Last eGFR (CKD-EPI): 91.2 [69.6–106.1] vs. 96.3 [75.6–111.1] <0.001

**Cause of death**
- Trauma: 150 (21.5) vs. 2333 (29.9) 0.001
- Stroke: 422 (60.4) vs. 3886 (49.7) 0.090
- Cardiac arrest: 30 (4.3) vs. 446 (5.7) 0.768
- Other: 97 (13.9) vs. 1147 (14.7) 0.002

**Hypertension**
- Yes: 157 (22.5) vs. 1505 (19.3) 0.002
- No: 321 (45.9) vs. 4211 (53.9) 0.001
- Not registered*: 221 (31.6) vs. 2096 (26.8) 0.001

**Diabetes**
- Yes: 36 (5.1) vs. 243 (3.1) <0.001
- No: 273 (39.1) vs. 4001 (51.2) 0.090
- Not registered*: 390 (55.8) vs. 3568 (45.7) 0.090

**Smoking**
- Yes: 247 (35.3) vs. 2870 (36.7) 0.737
- No: 206 (29.5) vs. 2826 (26.2) 0.001
- Not registered*: 246 (35.2) vs. 2116 (27.1) 0.768

**Cardiac arrest**
- Yes: 176 (25.2) vs. 1957 (25.1) 0.001
- No: 379 (54.2) vs. 4334 (55.5) 0.090
- Not registered*: 144 (20.6) vs. 1512 (19.5) 0.090

**Recipient**
- Age (yr): 51.6 ± 14.2 vs. 51.6 ± 14.1 0.937
- Sex (% male): 409 (58.5) vs. 4698 (60.9) 0.400
- Height (cm): 171.2 ± 10.5 vs. 171.4 ± 10.1 0.737
- Weight (kg): 76.8 ± 15.9 vs. 74.5 ± 15.0 0.001
- BMI (kg/m²): 26.4 ± 4.8 vs. 25.3 ± 4.4 <0.001

**Cause of renal failure**
- Diabetes: 57 (8.5) vs. 740 (9.9) 0.400
- Hypertension: 80 (11.9) vs. 881 (11.8) 0.001
- Glomerulonephritis: 84 (12.5) vs. 785 (10.5) 0.001
- (Polycystic kidney disease: 101 (15.1) vs. 1184 (15.9) 0.001
- Pyelonephritis: 57 (8.5) vs. 620 (8.3) 0.937
- IgA nephropathy: 21 (3.1) vs. 412 (5.5) 0.001
- Chronic renal failure, etiology unknown: 100 (14.9) vs. 1197 (16.0) 0.001
- Other: 171 (25.5) vs. 1651 (22.1) 0.737

**Preemptive**
- Yes: 19 (2.7) vs. 215 (2.8) 0.958
- No: 679 (97.1) vs. 7586 (97.1) 0.001

**Time on dialysis (yr)**
- <6: 601 (86.0) vs. 7040 (90.1) 0.001
- ≥6 and <85: 89 (12.7) vs. 707 (9.1) 0.001
- ≥85: 9 (1.3) vs. 63 (0.8) 0.001

**Panel reactive antibodies**
- <6%: 601 (86.0) vs. 7040 (90.1) 0.001
- ≥6 and <85: 89 (12.7) vs. 707 (9.1) 0.001
- ≥85: 9 (1.3) vs. 63 (0.8) 0.001

**Mismatches**
- HLA-DR
  - 0: 291 (41.8) vs. 3468 (44.5) 0.242
  - 1: 368 (52.8) vs. 3852 (49.5) 0.001
  - ≥2: 38 (5.3) vs. 465 (6.0) 0.001

**Transplant**
- First warm ischemic time (min)
  - EGL: 20.0 vs. 17.0 <0.001
  - Non-EGL: 28.0–45.0 vs. 26.0–40.0 0.001

**Cold ischemic time (h)**
- EGL: 22.0 vs. 19.1 <0.001
- Non-EGL: 16.7–27.3 vs. 14.0–24.5 0.001

**Graft anastomosis time (min)**
- EGL: 35.0 vs. 33.0 <0.001
- Non-EGL: 28.0–45.0 vs. 26.0–40.0 0.001

<table>
<thead>
<tr>
<th>EGL</th>
<th>Non-EGL</th>
</tr>
</thead>
<tbody>
<tr>
<td>n 699 (8.2%)</td>
<td>n 7812 (91.8%)</td>
</tr>
</tbody>
</table>

**HLA-A**
- 0: 209 (29.9) vs. 2762 (35.4) 0.010
- 1: 376 (53.9) vs. 3947 (50.6) 0.242
- ≥2: 113 (16.2) vs. 1087 (13.9) 0.001

**HLA-B**
- 0: 127 (18.2) vs. 2017 (25.9) <0.001
- 1: 413 (59.2) vs. 4255 (54.6) 0.001
- ≥2: 158 (22.6) vs. 1524 (19.5) 0.001

**RESULTS**

An evaluation of EGL was conducted in a cohort of 10,307 deceased donor kidney transplants that were performed between January 1, 1990 and January 1, 2018 in The Netherlands. Of these procedures, 8511 were primary transplant procedures. The observed incidence of EGL after a first kidney transplant was 8.2% (699 of 8511). Recipients with EGL received grafts from slightly older donors and had longer first warm and cold ischemic time (Table 1). The main reported causes of EGL were rejection (30.2%), primary nonfunction (25.0%), and thrombosis or infarction (20.3%) (Table 2).

Factors associated with EGL were explored using a multivariate regression analysis. Considering the procedural and potential biological differences between organs donated after brain death (DBD) and organs donated after circulatory death (DCD), these donor types were analyzed separately. Common risk factors for the development of EGL in both DBD and DCD transplant procedures were donor age, stroke as donor’s cause of death, and graft anastomosis time (Tables 3 and 4). Additional risk factors for the DCD transplant procedures were diabetes mellitus in the donor and the duration of first warm and cold ischemic time (Table 3). For
the DBD grafts, donor’s last serum creatinine, the number of years on dialysis before transplantation, and a panel reactive antibody (PRA) value ≥6% were found to further associate with EGL (Table 4). Donor characteristics, such as donor diabetes and cardiac arrest, are only registered from 2002 onward. As such, there is a high proportion of missing data (Supplementary Table S1). Additional sensitivity analyses of the multivariate models were performed for the 2002–2018 timeframe, which showed similar outcomes (Supplementary Tables 2A and B). Of note, formal significance was lost for the associations between donor age and stroke as cause of death and EGL in the DCD group (P = 0.07 and 0.09, respectively) (Supplementary Table S2A).

The consequences of EGL on mortality, relisting, retransplantation, and outcomes of retransplantation are summarized in Figure 1. EGL was associated with a significant increase in short-term mortality and compromised long-term patient survival. In fact, 30-day and 90-day mortality rates of the recipients with EGL were 5.2% and 11.7%, respectively (Figure 1), compared with 0.8% and 1.7% in the reference population (i.e., recipients without EGL after their first kidney transplant procedure). This survival disadvantage persisted in the long term, with a

Table 2 | Causes of early graft loss after first transplant procedures

<table>
<thead>
<tr>
<th>Causes of early graft loss</th>
<th>N = 699</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rejection</td>
<td>211 (30.2)</td>
</tr>
<tr>
<td>Primary nonfunction</td>
<td>175 (25.0)</td>
</tr>
<tr>
<td>Thrombosis or infarction</td>
<td>142 (20.3)</td>
</tr>
<tr>
<td>Technical or operative problems</td>
<td>96 (13.7)</td>
</tr>
<tr>
<td>Infection (graft- and nongraft-related)</td>
<td>12 (1.7)</td>
</tr>
<tr>
<td>Recurrent primary disease</td>
<td>10 (1.4)</td>
</tr>
<tr>
<td>Other</td>
<td>53 (7.6)</td>
</tr>
</tbody>
</table>

Data are presented as n (%).

Table 3 | Multivariate analysis (odds ratio [95% confidence interval]): risk factors associated with early graft loss after a first DCD transplant procedure

<table>
<thead>
<tr>
<th>Variables</th>
<th>Reference</th>
<th>Donor</th>
<th>P</th>
<th>Recipient</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>Reference</td>
<td>1.018 (1.003–1.034)</td>
<td>&lt;0.005</td>
<td>1.019 (1.001–1.039)</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>0.987 (0.969–1.006)</td>
<td>1.014 (0.978–1.050)</td>
<td>0.05</td>
<td>1.027 (0.999–1.051)</td>
<td>0.03</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>1.014 (0.999–1.011)</td>
<td>1.102 (0.715–1.698)</td>
<td>0.39</td>
<td>1.027 (1.014–1.040)</td>
<td>0.005</td>
</tr>
<tr>
<td>Last creatinine (µmol/l)</td>
<td>1.014 (0.999–1.011)</td>
<td>1.027 (1.014–1.040)</td>
<td>0.04</td>
<td>1.012 (0.967–1.060)</td>
<td>0.005</td>
</tr>
<tr>
<td>Hypertension</td>
<td>1.012 (0.967–1.060)</td>
<td>1.012 (0.997–1.059)</td>
<td>0.99</td>
<td>1.018 (1.003–1.034)</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>Diabetes</td>
<td>1.012 (0.967–1.060)</td>
<td>1.218 (1.074–1.985)</td>
<td>0.005</td>
<td>1.218 (1.074–1.985)</td>
<td>0.005</td>
</tr>
<tr>
<td>Cause of death</td>
<td>1.346 (0.715–2.627)</td>
<td>1.346 (0.639–2.832)</td>
<td>0.005</td>
<td>1.346 (0.639–2.832)</td>
<td>0.005</td>
</tr>
<tr>
<td>Transplant</td>
<td>1.090 (0.994–1.089)</td>
<td>1.108 (0.671–1.828)</td>
<td>0.005</td>
<td>1.108 (0.671–1.828)</td>
<td>0.005</td>
</tr>
<tr>
<td>Cause of death</td>
<td>1.013 (0.997–1.030)</td>
<td>1.392 (0.685–2.831)</td>
<td>0.01</td>
<td>1.392 (0.685–2.831)</td>
<td>0.01</td>
</tr>
<tr>
<td>Cause of renal failure</td>
<td>1.013 (0.997–1.030)</td>
<td>1.019 (0.989–1.049)</td>
<td>0.02</td>
<td>1.019 (0.989–1.049)</td>
<td>0.02</td>
</tr>
<tr>
<td>Cause of renal failure</td>
<td>1.013 (0.997–1.030)</td>
<td>1.027 (1.014–1.040)</td>
<td>0.005</td>
<td>1.027 (1.014–1.040)</td>
<td>0.005</td>
</tr>
<tr>
<td>Cause of renal failure</td>
<td>1.013 (0.997–1.030)</td>
<td>1.012 (0.967–1.060)</td>
<td>0.05</td>
<td>1.012 (0.967–1.060)</td>
<td>0.05</td>
</tr>
</tbody>
</table>

DBD, donation after brain death; HLA, human leukocyte antigen.

Table 4 | Multivariate analysis (odds ratio [95% confidence interval]): risk factors associated with early graft loss after a first DBD transplant procedure

<table>
<thead>
<tr>
<th>Variables</th>
<th>DBD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donor Age (yr)</td>
<td>1.030 (1.011–1.051)</td>
</tr>
<tr>
<td>Donor Height (cm)</td>
<td>0.978 (0.956–1.001)</td>
</tr>
<tr>
<td>Donor BMI (kg/m²)</td>
<td>0.966 (0.917–1.021)</td>
</tr>
<tr>
<td>Donor Last creatinine (µmol/l)</td>
<td>1.008 (1.004–1.013)</td>
</tr>
<tr>
<td>Donor Hypertension</td>
<td>0.985 (0.634–1.331)</td>
</tr>
<tr>
<td>Donor Cause of death</td>
<td>1.017 (0.365–2.832)</td>
</tr>
<tr>
<td>Recipient Age (yr)</td>
<td>1.002 (0.979–1.026)</td>
</tr>
<tr>
<td>Recipient BMI (kg/m²)</td>
<td>1.020 (0.943–1.104)</td>
</tr>
<tr>
<td>Recipient Cause of renal failure</td>
<td>1.034 (0.560–2.121)</td>
</tr>
<tr>
<td>Recipient Panel reactive antibodies ≥6%</td>
<td>2.502 (1.346–4.652)</td>
</tr>
</tbody>
</table>

DBD, donation after brain death; HLA, human leukocyte antigen.

Variables with P < 0.1 in the univariate analysis were entered.
significantly higher 10-year mortality risk (early-death censored) among the EGL recipients (adjusted hazard ratio [aHR], 1.68; 95% confidence interval [CI], 1.33–2.13; \( P < 0.001 \)) (Figure 2). Short-term and long-term patient survival after rejection-related or nonrejection-related EGL was similar (Supplementary Figure S1). Short-term and long-term causes of death are summarized in Table 5. The main causes of death were cardiovascular- and infection-related. The profound impact of EGL on patients experiencing EGL is clearly illustrated by a time of benefit of 5 years when compared with the estimated outcomes for patients on the waiting list (Figure 3).

Nearly three-quarters of the EGL recipients who survived 90 days after transplantation were relisted for re-transplantation, one-quarter did not return to the waiting list (Figure 1). The non-relisted recipients were approximately 10 years older than the relisted patients (Table 6). There were no indications that non-relisted patients were longer on dialysis before the initial transplant procedure (Table 6). Of the relisted patients, two-thirds were subsequently re-transplanted, resulting in an actual re-transplantation rate of 42.6% (Figure 1). The re-transplanted recipients were slightly younger compared with relisted not--re-transplanted recipients (mean age, 46.6 vs. 50.6 years, respectively) (Table 6). The proportion of immunized (45%) and highly immunized (24%) patients was equal in both groups (Table 6).

The analysis for re-transplantation showed a clear compromised outcome, with a doubled EGL incidence (16.8% vs. 8.2%, Figure 1). Among the re-transplanted patients, 83.2% were successfully re-transplanted (i.e., recipients without EGL after re-transplantation), resulting in an overall successful re-transplantation rate of 35.5% (Figure 1). For those successfully re-transplanted, 3-month and 1-year graft function (estimated glomerular filtration rate [eGFR]) was equal compared with the reference group (\( P = 0.33 \) and \( P = 0.26 \), respectively). Although long-term graft survival after re-transplantation was inferior (crude hazard ratio [HR], 1.47; 95% CI, 1.11–1.94), significance was lost after adjustment for potential confounders (aHR, 1.06; 95% CI, 0.62–1.81) (Figure 4). Subgroup analysis of long-term graft survival after rejection-related EGL showed a similar pattern: crude HR, 2.42; 95% CI, 1.59–3.70; and aHR, 1.71; 95% CI, 0.67–4.33 (Supplementary Figure S2).
Evaluation of a possible time effect showed a clear decrease in incidence of EGL over time ($P < 0.001$), yet the consequences of EGL were not influenced by time (Supplementary Table S3).

In the light of the profound impact of EGL, the question arises as to whether a more strict policy with regard to donor pool—quality by only accepting grafts with a minimal chance of EGL (and thus longer waiting lists) outweighs waiting list mortality. Data for the Dutch cohort studied herein allowed for the evaluation of the impact of the 8.2% a priori risk of EGL on recipient survival. Figure 5 shows that the 8.2% EGL risk for the Dutch donor pool minimally affects recipient survival (aHR [0% EGL is reference], 1.15; 95% CI, 0.99–1.34; $P = 0.07$) and that the consequences associated with a 8.2% EGL risk clearly outweighs simulated waiting-list mortality.

**DISCUSSION**

This nationwide evaluation characterizes EGL as a medical catastrophe that associates with a substantial short-term recipient mortality and poor long-term outcomes.

The profound benefits of kidney transplantation over dialysis on patient survival, quality of life, and costs—along with an aging population—have resulted in accruing waiting lists and increased waiting list associated mortality.3–6 Attempts to expand the donor pool come with higher incidences of delayed graft function (DGF), inferior function at 12 months, and (early) graft failure. Yet, although DGF is often regarded as a major impediment, recent cohort studies show that for DCD grafts, DGF does not impair long-term graft and patient survival and, consequently, that DGF in DCD grafts should be regarded an acceptable complication.7–9

Graft failure, on the other hand, is considered a disastrous complication of kidney transplantation. As such, an increased risk of graft failure—and particularly early graft failure—should be considered the primary impediment for a liberal use of deceased donor kidneys.

Yet, although several cohort studies show that EGL has a negative impact on patient survival,10–13 only 2 single-center, medium-sized (50 and 109 EGL cases, respectively) studies from the United Kingdom and Ireland systematically evaluated the further wide-ranging consequences of EGL.1,2 However, these studies were underpowered. Moreover, EGL was defined as graft nephrectomy or loss of transplant function within 30 days after transplantation.1,2 Although 30-day outcomes are generally used as primary outcomes for surgical complications, this time point may not accurately reflect the actual incidence of EGL. DGF may extend beyond 30 days,14–16 and a
considerable number of graft losses may only be diagnosed after 30 days.\textsuperscript{1,17} As a consequence, the 30-day time frame is too short to justify a robust medical decision, as the clinical diagnosis of EGL may be made at a time point beyond 30 days. In this context, we considered the 90-day time frame more appropriate, as regulations within Eurotransplant allow recipients with graft failure within 90 days to retain their initial pre-transplantation waiting times in case of relisting. Consequently, the 90-day time point hallmarks a strong external impetus for clinical decision-making with respect to the diagnosis of EGL. As such, it was decided to define EGL as functional graft loss within 90 days after transplantation. Based on this definition, we identified almost 700 recipients with EGL after their first kidney transplant in the national registry and performed a systematic, in-depth evaluation of the overall impact of EGL.

Although the overall incidence of EGL (8.2\%) in this evaluation suggests a 2.5-fold higher incidence than in the United States (3.4\%),\textsuperscript{11} it is important to bear in mind that this is partly due to a time-dependent effect with higher incidences of EGL in the earlier years.\textsuperscript{1} In fact, the incidence of EGL in The Netherlands for the corresponding time period (i.e., 2011 to 2015) is 5.4\%. The moderately higher incidence presumably reflects a more liberal attitude toward accepting DCD kidneys\textsuperscript{19} and the fact that the donors (for the 2011–2015 timeframe) are approximately 16 years older in The Netherlands than in the United States.\textsuperscript{11} It has to be noted that, although multivariate analyses mainly identified donor characteristics as risk factors for the development of EGL (Tables 3 and 4), the models only cover 14\% (for DCD) and 13\% (for DBD) of the variation by the explanatory variables as estimated by Nagelkerke R\textsuperscript{2}.\textsuperscript{19} This implies that the majority of causative factors are not captured by the current database and that, apart from donor and procedural factors, recipient factors also associate with the development of EGL. A notable aspect is the observed significant risk of EGL in recipients who received grafts from diabetic DCD donors (Table 3). Although this alarming finding obviously requires external confirmation, it calls for restraint in use of these donors. Although of interest, the available registry data did not allow further exploration of the negative impact of diabetes in DCD donors. One possible explanation for the phenomenon is that donor diabetes interferes with superior resilience responses observed in DCD donor kidneys.\textsuperscript{20}

This study confirms the findings of earlier studies with regard to the profound impact of EGL on patient survival. Whereas the Dutch registry data indicate a 30- and 90-day mortality rate of 1\% and 2\%, respectively, in the non-EGL group, an almost 7-fold higher incidence was observed in the EGL group. Although this high mortality may obviously be a direct consequence of EGL,\textsuperscript{2,21} the EGL-associated 90-day mortality also includes EGL that results from a recipient’s death. To be more specific, grafts in patients who died perioperatively are denied the opportunity to regain their function. Although the increased mortality may directly be related to surgical complications,\textsuperscript{2,22} it presumably also involves accumulation of recipient-related risk factors such as a higher age, poor (cardio)vascular status, and/or an increased frailty.\textsuperscript{23}

Apart from the immediate impact of EGL on mortality, the data indicate far-reaching, long-term consequences. Based on data from the Eurotransplant registry, 25\% of the recipients...
Table 6 | Comparison analyses of recipient characteristics

<table>
<thead>
<tr>
<th>Patients died ≤90 d after transplantation, n = 82</th>
<th>Non-relisted, n = 154</th>
<th>Relisted, not retransplanted, n = 142</th>
<th>Relisted and retransplanted, n = 298</th>
<th>Reference population, n = 7812</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (yr)</strong></td>
<td>57.3 ± 11.6</td>
<td>57.5 ± 12.6</td>
<td>50.6 ± 13.6</td>
<td>46.6 ± 14.2</td>
</tr>
<tr>
<td><strong>Sex (% male)</strong></td>
<td>60.0 [50.0–65.0]</td>
<td>60.0 [50.8–68.0]</td>
<td>53.5 [42.5–60.0]</td>
<td>48.0 [36.0–58.0]</td>
</tr>
<tr>
<td><strong>Body mass index (kg/m²)</strong></td>
<td>26.8 ± 4.8</td>
<td>27.2 ± 4.9</td>
<td>26.6 ± 4.8</td>
<td>25.7 ± 4.4</td>
</tr>
<tr>
<td><strong>PRA, panel reactive antibodies.</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Previous dialysis time before primary transplantation (yr)</strong></td>
<td>4.6 [3.2–6.2]</td>
<td>4.1 ± 2.0</td>
<td>4.4 ± 2.7</td>
<td>4.0 ± 2.0</td>
</tr>
<tr>
<td><strong>Preemptive primary transplantation (%)</strong></td>
<td>0</td>
<td>6 (4)</td>
<td>5 (4)</td>
<td>8 (3)</td>
</tr>
<tr>
<td><strong>Cause of renal failure</strong></td>
<td>n</td>
<td>%</td>
<td>n</td>
<td>%</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>12</td>
<td>15</td>
<td>16</td>
<td>10</td>
</tr>
<tr>
<td>Glomerulonephritis</td>
<td>6</td>
<td>7</td>
<td>14</td>
<td>9</td>
</tr>
<tr>
<td>Hypertension</td>
<td>16</td>
<td>20</td>
<td>20</td>
<td>13</td>
</tr>
<tr>
<td>IgA nephropathy</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>(Poly)cystic kidney disease</td>
<td>11</td>
<td>13</td>
<td>22</td>
<td>14</td>
</tr>
<tr>
<td>Pyelonephritis</td>
<td>4</td>
<td>5</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>20</td>
<td>24</td>
<td>38</td>
<td>25</td>
</tr>
<tr>
<td>Not specified</td>
<td>3</td>
<td>4</td>
<td>6</td>
<td>4</td>
</tr>
</tbody>
</table>

PRA, panel reactive antibodies.

*Most recent registered PRA percentage before the primary transplant procedure.

**Maximum PRA percentage registered after primary transplant procedure.

Data are presented as mean (±SD), median [interquartile range], or n (%).

with EGL were not relisted for re-transplantation. Reasons for not relisting are not captured in the Netherlands Organ Transplant Registry (NOTR) and Eurotransplant registry, and considerations are generally missing from patient records. Specified motivations for not relisting included patients’ preferences or recipient’s health status such as overall functional status or frailty, cardiovascular status or vascular condition. These aspects are reflected by the approximately 10-year older age of the non-relisted versus the relisted patients (Table 6).

One-third of the patients relisted after EGL did not undergo re-transplantation. Although this might be a slight overestimation, owing to some recipients with more recent EGL may be still awaiting re-transplantation, the majority of recipients is most likely removed from the waiting list because of worsening clinical condition or death. Although no specific information was available to what extent sensitization determines eligibility for relisting, sensitization status did not seem to influence the probability of re-transplantation among the relisted patients, as the number of immunized and highly immunized patients was equally distributed between the re-transplanted and non–re-transplanted groups.

Only 43% of the EGL patients had undergone re-transplantation. Outcomes for these re-transplantations are inferior compared with those of first kidney transplants. Noticeably, re-transplantation was associated with a doubled incidence of EGL (16.8% vs. 8.2% for primary transplantations and 9.1% for re-transplantations following late graft loss). This presumably reflects the convergence of risk factors within the individual patient, indicating that patients with EGL after a first transplant should be considered a high-risk recipient. This increased risk of recurrent EGL will obviously compromise the time to benefit for re-transplantations, an aspect that should be accounted for when considering re-transplantation.

In the light of the profound impact of EGL, the question arises whether a risk of EGL outweighs the waiting-list mortality. Although such an analysis is prone to confounding by indication, the cohort data allowed us to estimate the impact of the 8.2% a priori risk of EGL at the population level. It was concluded that, despite the profound impact of EGL for the individual recipient, the 8.2% incidence affected the population risk minimally. On this basis, it can be concluded that an optimal trade-off between the risk of EGL and waiting-list mortality is beyond an a priori EGL risk of 8.2% and that a policy aimed at minimizing incident EGL will lead to avoidable deaths as a result of longer waiting-list times.

A further question is whether patients who sustained EGL would have been better off with remaining on the waiting list. Although the data herein imply a time to benefit of 5 years after EGL, this poor outcome is actually a reflection of asymmetrical outcomes, with a strikingly high 6-month mortality for a subgroup of EGL recipients but favorable...
outcomes for EGL recipients surviving 6 months. One could speculate that the early mortality affects a subgroup of vulnerable recipients who were, in retrospect, better off staying on dialysis. In this context, accurate prediction tools aimed at identifying patients at risk of early death after EGL are an unmet medical need.30

Our study has some limitations, as this is a registry-based study. Although the NOTR is a mandatory registry for all 8 Dutch transplant centers, and several quality checks are performed, there are remaining missing data and registration errors. In addition, recipient factors of potential relevance, such as frailty, comorbidities, and cardiac and vascular state, are not included in the registry. Another limitation is that the vast majority of the patients in this evaluation are Caucasian. Given the profound impact of race on transplant outcomes, conclusions may not fully apply to non-Caucasians.31 Finally, conclusions are influenced by medical decision-making; kidneys with an anticipated risk of EGL are often declined before organ procurement (selection bias by allocation), and only a selective group of patients are considered eligible for relisting and re-transplantation (selection bias by indication).

In conclusion, the results in this nationwide study show that EGL after kidney transplantation is associated with...
significant detrimental consequences. These consequences include profound short-term and long-term mortality rates, a reduced chance of relisting and re-transplantation, and—for those re-transplanted—an increased risk of recurrent EGL. Although the development of EGL and the associated poor outcomes are generally attributed to the use of suboptimal kidney grafts, the data in this study also imply convergence of recipient risk factors in patients with EGL. As such, these recipient factors should specifically be accounted for when estimating the optimal trade-off at which the impact of EGL is balanced by maximizing the donor pool-size. With respect to the donor and procedural factors, the multivariate analyses performed show that, after the medical decision to accept the graft for donation, traditional risk factors minimally associate with incident EGL. Hence, there is an urgent need for complementary risk-assessment tools, such as biomarkers or ex vivo functional organ assessment, and possibly more extended risk prediction models.

METHODS

Study population
This study was approved by the local ethics committee of the Leiden University Medical Center. Data from all 11,415 deceased donor kidney transplant procedures performed between 1990 and 2018 were retrieved from NOTR. This nationwide, mandatory registry contains the data of all 8 Dutch kidney transplant centers. Registry follow-up is conducted at 3 months and 1 year after transplantation and annually thereafter. Procedures in recipients younger than 12 years of age (n = 261), combined organ procedures (n = 635), and uncontrolled circulatory death-donor procedures (Maastricht category 1, dead on arrival; and category 2, unsuccessful resuscitation) (n = 212) were excluded. The remaining 10,307 deceased donor kidney transplants were included in the analyses. For validation purposes and for correction of missing data, additional data of recipients with EGL was retrieved from Eurotransplant and Renal Replacement Registry (RENINE), the mandatory dialysis registry of The Netherlands, and incorporated in the final database.

Eurotransplant data for the 2009–2018 interval indicate a 1-year waiting list mortality of 11.03% ± 1.41% per year (mean ± SD) for patients on the active waiting list (kidney only) in The Netherlands, implying a relative risk of death of 2.51 compared with those successfully transplanted (observed 1-year mortality rate, 4.40%). Based on this relative risk, waiting-list survival curves were constructed using the Kaplan-Meier method to estimate waiting list survival times and 10- to 90-percentile intervals. This strategy was chosen, as waiting-list survival analyses may not be reliable beyond 1-year follow-up.

The Modification of Diet in Renal Disease (MDRD) equation was used to estimate GFR in the recipient. The eGFR in donors was estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

Definitions
In this study, EGL was defined as graft loss within 90 days after transplantation. Kidney transplant recipients who died within 90 days with a functioning kidney graft were not considered as EGL recipients. Recipients without EGL after their first kidney transplant procedure were considered the reference population. For ischemic periods of the donor kidneys, the following definitions were used: The first warm ischemic time in kidneys donated after circulatory death (DCD) is the time following the no-touch period after circulatory arrest and asystole until cold flush-out in the donor is commenced; the cold ischemia time is defined as the time from start of cold flush-out until the start of the vascular anastomosis at time of implantation in the recipient; the graft anastomosis time is the time from organ removal from static cold storage or hypothermic machine perfusion to reperfusion in the recipient. Immunized patients are patients who have PRA ranges of ≥6% and <85%.

Statistical analysis
IBM SPSS Statistics 23.0 (IBM Corp., Armonk, NY) was used for statistical analysis. Differences in donor, recipient, and transplant characteristics were analyzed using the Mann-Whitney rank test for nonparametric data, independent Student’s t test for normal distributed data and the chi-square test for categorical data. A multivariate regression analysis was used to identify factors associated with EGL. Variables with a P < 0.1 in the univariate analysis were entered in the multivariate regression analysis. Cox proportional hazards analyses, adjusted for clinically relevant variables (recipient age and sex) and statistical relevant variables (P < 0.1 in the univariate analysis), were performed to evaluate differences in patient- and death-censored graft survival. Patient survival was calculated from the date of transplant to the date of death (event), and patients were censored on the last day of follow-up, which was October 17, 2018. Survival time was truncated at 3 months or 10 years. Graft survival was calculated from the date of transplant to the registered date of graft failure (event). Patients were censored at the time of patient’s death or at the time of last day of follow-up. Kaplan-Meier survival curves were generated for all groups of interest. Results are represented as aHR for the patient and graft survival analyses, and as odds ratio (OR) for the multivariate regression analysis with the corresponding 95% CI. In this study, missing data—coded as unknown for categorical variables—were excluded from analyses. For variables of primary interest (EGL, cause of EGL, and short-term patient and graft survival), there were no missing values. The frequency of missing data for secondary variables is shown in Supplementary Table S1. To exclude a possible missing data-related bias, additional sensitivity analyses were performed for different timeframes. P values < 0.05 were considered statistically significant.

DISCLOSURE
All the authors declared no competing interests.

ACKNOWLEDGMENTS
The authors gratefully acknowledge the Dutch Transplant Foundation (Nederlandse Transplantatie Stichting) for providing the data. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

SUPPLEMENTARY MATERIAL

Table S1. Proportion of missing data.
Table S2A. Multivariate sensitivity analysis including data from 2002 to 2018 (odds ratio [95% CI]): risk factors associated with early graft loss after a first DCD transplant procedure.
Table S2B. Multivariate sensitivity analysis including data from 2002 to 2018 (odds ratio [95% CI]): risk factors associated with early graft loss after a first DBD transplant procedure.
Table S3. Time-related changes in incidence and consequences of early graft loss.

Figure S1. Landmark analysis of short-term and long-term patient survival following rejection resp. nonrejection-related EGL.

Figure S2. Death censored 10-year graft survival following successful retransplantation after primary rejection resp. nonrejection-related EGL.

REFERENCES


